Optimising patient care in atrial fibrillation
In this CPD-accredited report, Professor Marc Bonaca of the University of Colorado shares current opinion on thromboprophylaxis for stroke prevention in AF patients
You will learn:
• To consider the differences between trial-related factors and drug-related factors in the major direct oral anticoagulant (DOAC) trials and the value of meta-analyses
• That real-world data are useful for descriptive analyses and event rates, although caution is required for non-randomised comparisons of drug effects
• That all DOACs are of similar efficacy and their use is generally supported by guidelines for stroke prevention in the patient with atrial fibrillation (AF).
WEBINAR HELD ON 22 JUNE 2021
ATTENTIONKindly note that if you attended the live webinar, you have already received 1 CPD point and will not be permitted to receive additional points for the report. Should this occur, the HPCSA will only record the 1 CPD point from the live webinar, invalidating any additional CPD points from the report.
Please note deNovo Medica ensures uploading of your CPD points to the HPCSA: please don’t upload these yourself.
To access this module, please register or login: